Ioannis Tassiulas
Video Visit Available
Accepting New Patients
Mount Sinai Verified Doctors IconMount Sinai DoctorsTreats Adults

Ioannis Tassiulas, MD, PhD

Rheumatology

White Phone Icon212-241-1671
Calender Icon
Book an Appointment
White Right Arrow

About Me

Aristotle University Medical School, Thessaloniki, Greece 1991.

Research Fellowship in Immunology at the National Institute of Arthritis Musculoskeletal and Skin Diseases/NIH, Bethesda MD (1995-1997).

Internal Medicine residency at Albert Einstein MedicalCenter, Philadelphia PA (1997-2000).

Fellowship in Rheumatology at the Hospital for Special Surgery/Cornell, New York,NY (2000-2003).

Assistant professor of Medicine at the Hospital for Special Surgery (2003-2007).

Senior Investigator at the Institute of Molecular Biology/University of Crete Medical School, Greece (2007-2011)

Associate Professor of Medicine, New York Medical College, Valhalla, NY (2011-2015)

Associate Professor of Medicine, Icahn School of Medicine at Mount Sinai (2015-)
Language
English, Greek
Position
ASSOCIATE PROFESSOR | Medicine, Rheumatology
Hospital Affiliations
  • Mount Sinai Beth Israel
  • Mount Sinai Morningside
  • Mount Sinai Brooklyn
  • Mount Sinai Queens
  • The Mount Sinai Hospital
  • Mount Sinai West

Clinical Focus

Show More

Education

MD, Aristotle University of Thessaloniki
Residency, Internal Medicine

Albert Einstein College of Medicine-Yeshiva University

Fellowship, Rheumatology

Hospital for Special Surgery

Certifications

American Board of Internal Medicine

Awards

2009

EULAR Basic Sciences Abstract Award

2005

The Charles Christian Research Fellowship

2003

ACR Rheumatology Fellow Award

2002

Rheumatology Fellowship Award

Amgen

2002

Abbott Scholar Award in Rheumatology Research

1996

American Society of Nephrology Blue Ribbon Award

1996

American College of Rheumatology (ACR) Research and Education Foundation Award

Research

Cytokines and the Jak-STAT signaling pathway.

Cytokines are secreted proteins that mediate communication between cells and are critical for the development and regulation of the immune response. Cytokines act by binding with high affinity and specificity to cell surface receptors, triggering signal transduction pathways that ultimately lead to gene activation cascades that regulate cellular activation, differentiation, proliferation and survival. Deregulation of cytokine production or cytokine networks have been implicated in the pathogenesis of a number of human autoimmune/ inflammatory diseases including SLE.
Cytokines relay their intracellular signals by utilizing the Jak-Stat signal transduction pathway. The binding of the cytokines to their receptors that lack intrinsic kinase activity, activates Janus kinases (Jaks), protein tyrosine kinases that are associated with the receptor. Typically each cytokine activates a distinct pair of of two of the four known Jaks. Jak kinases are required for tyrosine phosphorylation and activation of latent cytoplasmic transcription factors termed signal transducers and activators of transcription (STATs). After cytokine stimulation, STATs are rapidly tyrosine phosphorylated, and subsequently dimerize and translocate to the nucleus, where they can activate gene transcription. Tyrosine phosphorylation of STATs is essential for activation, dimerization and DNA binding.
We have shown that IFN signaling is regulated by crosstalk with the ITAM-Syk pathway, a signal transduction pathway that is used specifically by immune cells and is key in cell activation. Crosstalk between IFN and Syk-mediated pathways is not static but depends on the activation state of macrophages and is induced by priming with IFN (Fig. 2). Thus, macrophage responses to IFN are determined by integration of signals from two main pathways that regulate immune responses (1).
Thus, the nature of cytokine responses can be altered or reprogrammed by the nature of a particular stimulus or the microenvironment that the cells are exposed.

Immune cell receptors

A growing number of receptors including the Toll-like receptors (TLRs) and receptors that transmit signals via the ITAM containing adaptor molecules FcR and DAP12 play important roles in the activation status of the cells of the immune system. Activation of these receptors by their ligands seems to be very important for effective development and resolution of an immune response. Signaling pathways activated downstream of these receptors include the NF-kB, MAPKs, PI3K and Ca++-induced pathways that play a central role in the activation, differentiation and survival of the cells. There is experimental evidence of regulation and crosstalk between cytokine and immune receptor signaling in cells of the immune system. A paradigm is the inhibition of interleukin-10 (IL-10) signaling in macrophages after ligation of the FcgRs by immune complexes (2). In this case macrophages become refractory to the anti-inflammatory actions of IL-10, a mechanism that may play important role in the perpetuation of inflammation in diseases characterized by the presence of immune complexes such as inflammatory arthritis and systemic lupus erythematosus.

Tpl2 kinase

Tumor progression locus 2 (Tpl2) encodes a serine/threonine protein kinase that is activated by provirus integration in Moloney murine leukemia virus-induced T cell lymphomas and mouse mammary tumor virus-induced mammary adenocarcinomas. Tpl2 transduces Toll-like and death receptor signals in a variety of cell types and plays an important role in innate immunity and inflammation. Tpl2 knockout (Tpl2-/-) mice develop normally and have no obvious phenotypic defects. However, Tpl2-/- mice are resistant to LPS-induced endotoxin-shock, as well as to TNF-induced inflammatory bowel disease. Tpl2 plays an obligatory role in the transduction of extracellular signal-regulated kinase (ERK) activation signals induced by LPS and CD40L inmacrophages and B cells and by TNF in macrophages. The failure of ERK activation by LPS in Tpl2-/- macrophages gives rise to defects in the expression of cytokines, chemokines and other molecules involved in the regulation of innate and adaptive immunity.
We have shown that Tpl2 kinase is activated downstream of the FcgRs and regulate phagocytosis and cytokine and chemokine production. Moreover in an animal model of immune thrombocytopenia pharmacological targeting of Tpl2 prevented the development of thrombocytopenia. These data identify Tpl2 kinase as a potential therapeutic target for autoimmune diseases.

Locations

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Patients with Cigna Medicare Advantage or Humana Medicare Advantage insurance: Please read this important message before booking to find out if out-of-network costs may apply to your next visit.

  • Mount Sinai Doctors Westchester341 Central Park Avenue, Scarsdale, NY, 10583
    Down Arrow
  • 17 East 102nd Street, 2nd Floor, New York, NY, 10029
    Down Arrow

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Publications:23
Selected Publications

Patient Experience Star Ratings and Comments

The Patient Experience Star Rating reflects our patients’ perception of how well their Mount Sinai provider communicated with them during an office visit. The Star Rating is based on patient responses to three questions on a patient experience survey, a standardized questionnaire sent to verified patients and distributed by a third party vendor, Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score.


Care Provider’s Explanation

Care Provider’s Concern

Likelihood to Recommend Care Provider

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Tassiulas has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.